Skip to main content
ESOT Congress, Vienna | Sept 8-11
2, Aug 2013

ESOT Congress, Vienna-Plexision’s pharma collaboration to be reported ...

Results from Plexision’s pharma collaboration to be reported at the European Society for Organ Transplantation Congress, Vienna | September 8-11


Optimizing the effectiveness of a new immnosuppressant requires usage, which is informed by an understanding of individual rejection-risk and response to the drug. This knowledge can facilitate the design of novel regimens based on the new immunosuppressant, and the selection of patients suited for such regimens.

Plexision provides PK/PD services and dose-response modeling as the bases for drug target selection and development of companion diagnostics.

The European Society of Transplantation (ESOT) is a premier organization whose members include healthcare providers involved in the care of transplant patients in Europe and internationally.


Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to

  • - Assess disease risk for several immunological disorders.
  • - Predict the success of a drug for a specific patient.
  • - Develop dosing recommendations for new immunological drugs.

Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.